Abstract: A method for determining the risk of developing a blood disorder, which includes the steps of: exposing a biological sample from an individual to radiation to obtain a spectrum characteristic of the sample, the spectrum being processed in order to obtain a spectral signature; comparing the spectral signature obtained with one or more reference spectral signatures; and concluding, if the spectral signature of the individual is significantly different from control spectral signatures, that the individual is likely to develop a blood disorder, and, if not, that the individual is not likely to develop a blood disorder.
Type:
Application
Filed:
May 24, 2021
Publication date:
July 27, 2023
Applicants:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS, UNIVERSITÉ DE TOURS
Abstract: New human therapeutic monoclonal antibodies, which are directed against neutrophil proteinase 3. The monoclonal antibodies are specifically directed against a conformational epitope of the neutrophil proteinase 3 and are capable of inhibiting by at least 30% the production for reactive oxygen derivatives by neutrophils. Also, a pharmaceutical composition including as an active substance at least the monoclonal antibody, and a method for early treatment and/or prevention of relapse of granulomatosis with polyangiitis, which includes the administration of the pharmaceutical composition.
Type:
Application
Filed:
October 16, 2020
Publication date:
June 29, 2023
Applicants:
UNIVERSITE DE TOUR, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Abstract: A method for predicting the risk of prostate cancer recurrence in a subject affected with prostate cancer, including: (a) providing a sample from the subject, (b) determining the TMPRSS/ERG fusion status of the sample, (c) if the sample is positive for TMPRSS/ERG fusion (Fus+), determining a molecular signature of the sample by measuring the expression level of at least 6 prostate cancer markers selected from the ANPEP, AZGP1, CHRNA2, COMP, KHDRBS3 and SFRP4, (d) comparing the molecular signature to a reference signature, and (e) assigning the subject to a risk group based on the correlation of the molecular signature with the reference signature, thereby predicting the risk of cancer recurrence in the subject.
Type:
Application
Filed:
January 25, 2019
Publication date:
February 11, 2021
Applicants:
SORBONNE UNIVERSITE, CTRE RECHERCHE PATHOLOGIES PROSTATIQUES, LIGUE NATIONALE CONTRE LE CANCER, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE TOURS, CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE TOURS
Abstract: The invention relates to compounds of formula (II) for using in imaging and particularly for the diagnosis of neurodegenerative diseases.
Type:
Grant
Filed:
September 26, 2017
Date of Patent:
February 2, 2021
Assignees:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'ORLEANS, UNIVERSITE DE TOURS, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
Inventors:
Sylvain Routier, Franck Suzenet, Sylvie Chalon, Frederic Buron, Johnny Vercouillie, Ronald Melki, Liliana Boiaryna, Denis Guilloteau, Laura Pieri
Abstract: An immunogenic fusion protein includes at least the following two peptides a) —on the C-terminal side, a first peptide constituted of: —the amino acid sequence of the protein S or the protein M of a human hepatitis B virus (HBV) isolate, which protein S or protein M is optionally deleted at the N-terminal end thereof, and b) —on the N-terminal side, a second peptide constituted of: —the sequence of amino acids of at least one transmembrane domain and the ectodomain of at least one protein of a Zika virus isolate selected from the envelope protein E or a fusion peptide including the envelope protein E and the protein prM.
Type:
Grant
Filed:
June 16, 2017
Date of Patent:
September 8, 2020
Assignees:
UNIVERSITE DE TOURS, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE—INSERM
Inventors:
Christophe Hourioux, Romuald Patient, Elodie Beaumont, Philippe Roingeard
Abstract: Methods are provided to determine the cancer prognosis of subjects and/or to adapt the treatment protocol of subjects having or susceptible to cancer. Embodiments include the steps of determining in vitro the genotype of said subject at a polymorphism in the C3-ITGAM axis, making a cancer prognosis of the subject based on said genotype and selecting an anti-cancer treatment for the subject.
Type:
Application
Filed:
December 4, 2009
Publication date:
February 2, 2012
Applicants:
Centre Hospitalier Regional Universitaire de Tours, Universite Francois Rabelais de Tours